### Supplementary Table I

| Anti-human | Fluorochrome<sup>A</sup> | Clone | Brand            |
|------------|--------------------------|-------|------------------|
| CD1a       | Purified                 | EP3622| Roche-Ventana    |
| CD3        | APC                      | SK7   | BD Biosciences   |
| CD4        | FITC                     | RPA-T4| BD Pharmingen    |
| CD4        | Purified                 | SP35  | Roche-Ventana    |
| CD8        | PerCP                    | SK1   | BD Biosciences   |
| CD8        | Purified                 | SP57  | Roche-Ventana    |
| CD69       | PE                       | FN 50 | BD               |
| Granzyme B | Purified                 | Polyclonal | Roche-Ventana |
| GATA-3     | Purified                 | L50-823| Roche-Ventana   |
| IFN-γ      | Purified                 | MD-1  | Biolegend        |
| IL-2       | Purified                 | Component | BD Biosciences |
| IL-5       | Purified                 | TRFK5 | Biolegend        |
| Perforin   | Purified                 | dG9   | Abcam            |
| T-bet      | Purified                 | 4B10  | BD Pharmingen    |

**Notes.** <sup>A</sup> Allophycocyanin (APC), peridinin chlorophyll (PerCP), fluorescein isothiocyanate (FITC), phycoerythrin (PE). NA, not available.
Supplementary FIG 1. Mixed profiles of cytokines and chemokines in the sera of patients with Chagas disease with adverse skin reactions during treatment with benznidazole. Serum samples were taken prior to treatment (t0), at 7-30 days (t17-30d) and at 3-12 months (t3-12m) after initiation of treatment in *T. cruzi*-infected subjects with moderate/severe dermatitis [A, (+) DM] or without skin reactions [B, (−) DM] during benznidazole therapy. Plots exhibit representative data for single subjects with (TI42 and TI61) or without (TI119 and TI120) ADRs.
Supplementary FIG 2. CBA assays for the measurement of cytokines and chemokines in the sera of patients with Chagas disease treated with benznidazole. Serum samples were taken prior to treatment (t0), at 7-30 days (t17-30d) and 3-12 months (t3-12m) after initiation of treatment in *T. cruzi*-infected subjects with moderate/severe (+ DM; n=11) or without (— DM, n=11) skin reactions during benznidazole therapy and in the uninfected subjects (UI, n=14). Each point represents the concentration values for a single subject for each soluble factor evaluated: granzyme B (A), IL-13 (B), MCP-1 (C), RANTES (D) and IL-8 (E). No differences were recorded among time points posttreatment or between *T. cruzi*-infected and uninfected groups.